How does the new study’s approach to extending ketamine’s antidepressant effects differ from previous methods?
Imagine a treatment for major depressive disorder (MDD) so effective it coudl lift the darkest clouds, not for days, but for months. This isn’t science fiction; it’s the tantalizing promise of cutting-edge research aiming to revolutionize MDD treatment. Consider this: roughly one in ten Americans struggles with MDD at any given time, and a significant portion finds existing treatments — such as antidepressants — ineffective, leaving many trapped in a cycle of despair. Now, a groundbreaking study published in Science offers a beacon of hope, suggesting we might potentially be on the cusp of extending the efficacy of ketamine, a rapidly acting antidepressant, from mere days to an impressive two months. This innovative approach targets and enhances a specific cellular pathway, possibly transforming the landscape of mental health treatment.
Yet despite its prevalence, methods to treat MDD often fall short for a not-insignificant portion of the population. Antidepressants — the standard of treatment — don’t work for 30 percent with MDD.
When infused at a low dose ketamine shows remarkable efficacy as a rapidly acting antidepressant, with effects observed within hours even in patients who have been resistant to other antidepressant treatments. Though, consistent infusions of ketamine are needed to maintain symptoms at bay, which could result in side effects, such as dissociative behaviors and the possibility of addiction, and stopping treatment can result in relapse.
In a new study published in ScienceLisa Monteggia’s and Ege Kavalali’s labs show that it is feasible to substantially extend the efficacy of a single dose of ketamine from its current duration of up to a week to a longer period of up to two months.
“The premise of this study, which was led by Zhenzhong Ma, a fantastic research assistant professor, was based on a testable mechanistic model that we developed that accounts for ketamine’s rapid antidepressant action,” Monteggia said.Monteggia holds the Lee E. limbird Chair in Pharmacology and is the Barlow Family Director of the Vanderbilt Brain Institute.
Previously, researchers in the field had steadfast that ketamine’s antidepressant effect requires the activation of a key signaling pathway called ERK, but only ketamine’s long-term effects — not its rapid effects — are abolished when ERK is inhibited. As a fast-acting antidepressant, ketamine relies on ERK-dependent synaptic plasticity to produce its rapid behavioral effects. Ma and colleagues hypothesized that they could maintain ketamine’s effects for longer periods by enhancing ERK activity.
In the recent paper, Ma discovered that ketamine’s antidepressant effects could be sustained for up to two months by using a drug called BCI, which inhibits a protein phosphatase and results in increased ERK activity. By inhibiting the phosphatase,the authors retained ERK’s activity and augmented the synaptic plasticity that drives ketamine’s prolonged antidepressant effects.
Even though the use of BCI make the request of these results to the clinic tough, Monteggia said that the results provide a proof of principle that ketamine’s antidepressant action can be sustained by targeting intracellular signaling. She and Kavalali, the William Stokes Professor of Experimental Therapeutics and the chair of the Department of Pharmacology, have worked on the project since its inception and hope that it fosters other studies looking to identify specific molecules that will enhance and sustain the action of a single dose of ketamine.
Ultimately, this work will be a steppingstone toward improving MDD patients’ lives by reducing the burden of treatment.
Graduate student Natalie Guzikowski and postdoctoral fellow Ji-Woon Kim were coauthors on the study.
Roughly 10 percent of the U.S. population is afflicted with major depressive disorder at any given time, and up to 20 percent will exhibit MDD symptoms over their lifetimes.
Yet despite its prevalence, methods to treat MDD often fall short for a not-insignificant portion of the population. Antidepressants — the standard of treatment — don’t work for 30 percent with MDD.
When infused at a low dose ketamine shows remarkable efficacy as a rapidly acting antidepressant, with effects observed within hours even in patients who have been resistant to other antidepressant treatments. However, consistent infusions of ketamine are needed to maintain symptoms at bay, which could result in side effects, such as dissociative behaviors and the possibility of addiction, and stopping treatment can result in relapse.
In a new study published in ScienceLisa Monteggia’s and Ege Kavalali’s labs show that it is feasible to substantially extend the efficacy of a single dose of ketamine from its current duration of up to a week to a longer period of up to two months.
“The premise of this study, which was led by Zhenzhong Ma, a fantastic research assistant professor, was based on a testable mechanistic model that we developed that accounts for ketamine’s rapid antidepressant action,” Monteggia said. Monteggia holds the Lee E. Limbird Chair in Pharmacology and is the Barlow Family Director of the Vanderbilt Brain Institute.
Previously, researchers in the field had determined that ketamine’s antidepressant effect requires the activation of a key signaling pathway called ERK, but only ketamine’s long-term effects — not its rapid effects — are abolished when ERK is inhibited. As a fast-acting antidepressant, ketamine relies on ERK-dependent synaptic plasticity to produce its rapid behavioral effects. Ma and colleagues hypothesized that they could maintain ketamine’s effects for longer periods by enhancing ERK activity.
In the recent paper, Ma discovered that ketamine’s antidepressant effects could be sustained for up to two months by using a drug called BCI, which inhibits a protein phosphatase and results in increased ERK activity. By inhibiting the phosphatase, the authors retained ERK’s activity and augmented the synaptic plasticity that drives ketamine’s prolonged antidepressant effects.
Although the use of BCI make the application of these results to the clinic difficult, Monteggia said that the results provide a proof of principle that ketamine’s antidepressant action can be sustained by targeting intracellular signaling. She and Kavalali, the William Stokes Professor of Experimental Therapeutics and the chair of the Department of Pharmacology, have worked on the project since its inception and hope that it fosters other studies looking to identify specific molecules that will enhance and sustain the action of a single dose of ketamine.
Ultimately, this work will be a steppingstone toward improving MDD patients’ lives by reducing the burden of treatment.
Graduate student Natalie Guzikowski and postdoctoral fellow Ji-Woon Kim were coauthors on the study.